USFDA nod to Pfizer Beqvez for adults with Hemophilia B
New York: Pfizer Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis therapy, …